AI Market Cap Pro
← Back to Scanner Pricing
📅 Next earnings: October 30, 2026

Regeneron Pharmaceuticals, Inc. (REGN) — Pre-Earnings Stock Analysis

Healthcare, Biotechnology

$752.85
Current Price
$77.5B
Market Cap
18.6
Trailing P/E
$860
Analyst Target
26
Analysts
Buy
Rating

🔥 Get REGN Targets Before Earnings

Pre-earnings entry zone, analyst PE target, 3-day and 5-day implied move, and stop loss — all unlocked with a $5/month subscription.

Unlock Full Analysis →

About Regeneron Pharmaceuticals, Inc. (REGN)

Regeneron Pharmaceuticals, Inc. trades on NASDAQ under the ticker REGN. The company operates in the Healthcare sector — specifically Biotechnology.

Current analyst consensus rating: Buy with a $860 price target based on 26 analyst opinions.

EPS (trailing): $40.44  |  Market Cap: $77.5B

Healthcare Biotechnology

Pre-Earnings Trading Strategy for REGN

Trading stocks before earnings requires understanding three key variables: the implied move (what the options market expects), the historical beat rate for the sector, and the current momentum leading into the report.

For REGN, the next earnings report is scheduled for October 30, 2026.

The implied move is calculated using at-the-money straddles — if the straddle is priced at X%, the market is pricing in approximately a ±X% move in either direction around the earnings release.

How AI Market Cap Finds Pre-Earnings Setups

Our pre-earnings momentum scanner scores REGN across five factors to identify high-conviction setups:

The Pro subscription shows the full target range, stop loss, and implied move for REGN and all 20+ stocks in the current earnings window.